Original article
Type 2 Diabetes does not worsen prognosis in hepatocellular carcinoma

https://doi.org/10.1016/j.clinre.2010.11.002Get rights and content

Summary

Introduction

Type 2 Diabetes (T2DM) is associated with liver inflammation and carcinogenesis. The prevalence of T2DM among patients with liver cirrhosis and hepatocellular carcinoma is increasing. However, the effect of T2DM on the natural history of hepatocellular carcinoma is not known.

Aim

To examine the effect of T2DM on hepatocellular carcinoma (HCC) survival in treated and untreated disease.

Methods

Retrospective analysis was performed on HCC cases diagnosed during 2000–2005, and prospectively during 2006–August 2007. Demographics, HCC staging, response to treatment, and survival were collected. A comparison was made between patients with T2DM and without T2DM.

Results

One hundred and thirty-five patients were recruited in total; 58 (43%) had T2DM. Seventy (37 diabetic) patients were treated with percutaneous radiological therapies, with 168 treatments given. Treatment was determined by AASLD guidelines and patient tolerance, there was no randomisation. There was no significant difference in survival between diabetic and nondiabetic patients. There was a nonsignificant trend towards greater survival in diabetic patients (overall median survival diabetics 21 mths vs nondiabetics 5 mths, P = 0.355).

Conclusions

T2DM does not negatively impact on the natural history of treated or untreated HCC.

Introduction

Hepatocellular carcinoma (HCC) is an important major public health issue, with the incidence and mortality increasing in all areas of the world, including Europe, Japan, USA and Australia [1]. Worldwide, it is the fourth most common cancer and third most common cause of cancer-related death [2]. Survival is poor, reflecting the aggressive nature of HCC, frequency of late diagnosis and availability of limited treatment options for advanced disease [3]. Ablative treatments with alcohol, radiofrequency ablation (RFA) or transarterial chemoembolisation (TACE) have been demonstrated to control progression of disease and in some studies improve survival [4], [5], [6].

Type 2 diabetes (T2DM) is relatively common in patients with cirrhosis and its role in fibrosis progression in NASH related cirrhosis is an area of active research. T2DM is a risk factor for all cancer types, including HCC [7], [8]. However, the impact of T2DM on the natural history of HCC is not known. With the current global epidemic of the metabolic syndrome and T2DM, even a small attributable risk has the potential to lead to large increases in HCC burden worldwide [9].

As T2DM is associated with significant co-morbidities, we hypothesized that the survival would be compromised in this subgroup. Therefore, the aim of this study was to investigate outcomes of patients with HCC and T2DM compared to nondiabetics.

Section snippets

Patients

All patients diagnosed with HCC at The Royal Melbourne Hospital, Melbourne, Australia, between 1st January 2000 and 31st August 2007 were included in this study. Ethics approval was obtained from Melbourne Health Research Directorate Human Ethics Committee. Data was collected retrospectively between 1st January 2000 and 31st December 2005, and prospectively from 1st January 2006 to 31st August 2007. Diagnosis of HCC was established on positive histopathology of liver biopsy or surgical resection specimen,

Demographic, clinical and tumour features

Demographic, clinical and tumour features of the HCC cohort are shown in Table 1. Cirrhosis was present in 91.1%; all those without cirrhosis had chronic hepatitis B. Alcohol was the most commonest cause of underlying cirrhosis (40.7%) followed by hepatitis C (35%), NASH (23.6%) and hepatitis B (22.8%). The “other” category included two cases of Alagille syndrome and one case of cardiac cirrhosis. Diabetes was present in 43% of our patients (54 had T2DM, four had Type 1 diabetes (T1DM). Only

Discussion

This study examines whether diabetes impacts on the natural history of HCC. Patients with diabetes frequently have significant comorbidities which may complicate treatment of HCC, and diabetes is recognised to be an independent risk factor for HCC. Our hypothesis that diabetic patients would have poorer outcomes was not confirmed by this study. Diabetes did not appear as a statistically significant factor when linked with survival in either treated patients, untreated patients or the overall

Conclusion

Patients with T2DM and HCC had similar outcomes compared to nondiabetics with HCC. There was a nonsignificant trend towards longer survival in diabetics compared to nondiabetics with HCC, despite greater comorbidities in the diabetic cohort.

Conflict of interest statement

The authors have no disclosures or conflict of interest.

Acknowledgements

We would like to thank The Cancer Epidemiology Centre, Victorian Cancer Registry, The Cancer Council Victoria, Melbourne, Australia for providing accurate dates of death for our cohort.

We would also like to thank Kaye Marion for her assistance with some of the survival curves used in this article.

References (22)

  • J. Llovet et al.

    Hepatocellular carcinoma

    Lancet

    (2003)
  • D. Brown et al.

    Society of Interventional Radiology position statement on chemoembolisation of hepatic malignancies

    J Vasc Interv Radiol

    (2006)
  • S.K. Roberts et al.

    Hepatocellular carcinoma in an Australian tertiary referral hospital 1975–2002: change in epidemiology and clinical presentation

    J Gastroenterol Hepatol

    (2007)
  • H. El-Serag

    Hepatocellular carcinoma, an epidemiological view

    J Clin Gastroenterol

    (2002)
  • T. Livraghi et al.

    Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection

    Radiology

    (1995)
  • T. Livraghi et al.

    Sustained complete response and complication rates after radio-frequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?

    Hepatology

    (2008)
  • C. Camma et al.

    Trans-chemoembolisation for unresectable hepatocellular carcinoma: meta-analysis of randomised-controlled trials

    Radiology

    (2002)
  • J. Tazawa et al.

    Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C

    Dig Dis Sc

    (2002)
  • B. Veldt et al.

    Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus

    Hepatology

    (2008)
  • E. Bugianesi

    Review article: steatosis, the metabolic syndrome and cancer

    Aliment Pharmacol Ther

    (2005)
  • S. Chitturi et al.

    Nonalcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines

    J Gastroenterol Hepatol

    (2007)
  • Cited by (7)

    • Pre-existing type-2 diabetes is not an adverse prognostic factor in patients with renal cell carcinoma: A single-center retrospective study

      2013, Urologic Oncology: Seminars and Original Investigations
      Citation Excerpt :

      In our experience, the presence of DM has not had an impact on prognosis, with progression and RCC-related mortality rates being virtually equivalent to DM-free cases. This finding is in line with the results of several studies on surgical series of colon and liver cancer that did not confirm the negative prognostic role of DM detected in population studies [26,27]. It should be remarked that population studies, though benefiting from larger cohorts, suffer from the biases related to the heterogeneous sets of diagnoses and treatments among patients.

    View all citing articles on Scopus
    View full text